BRPI0418765B8 - composto da fórmula (i) e composição farmacêutica - Google Patents

composto da fórmula (i) e composição farmacêutica

Info

Publication number
BRPI0418765B8
BRPI0418765B8 BRPI0418765A BRPI0418765A BRPI0418765B8 BR PI0418765 B8 BRPI0418765 B8 BR PI0418765B8 BR PI0418765 A BRPI0418765 A BR PI0418765A BR PI0418765 A BRPI0418765 A BR PI0418765A BR PI0418765 B8 BRPI0418765 B8 BR PI0418765B8
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
inhibiting
tgf
formula
Prior art date
Application number
BRPI0418765A
Other languages
English (en)
Inventor
Kim Dae-Kee
Kim Hun-Taek
Cho Il-Sang
Hun Choi Joon
Park Myoung-Soon
Jae An Young
Bang Yung-Jue
Original Assignee
Ewha Univ Collaboration Foundation
Sk Chemicals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ewha Univ Collaboration Foundation, Sk Chemicals Co Ltd filed Critical Ewha Univ Collaboration Foundation
Publication of BRPI0418765A publication Critical patent/BRPI0418765A/pt
Publication of BRPI0418765B1 publication Critical patent/BRPI0418765B1/pt
Publication of BRPI0418765B8 publication Critical patent/BRPI0418765B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Structural Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)

Abstract

composto, composição farmacêutica, método de inibir o tgf-b, método de reduzir o acúmulo de excesso de matriz extracelular, método de inibir metástase de células tumorais, método de tratar carcinomas, método de tratar uma doença, pró-droga, método de inibir trombose. esta invenção refere-se a imidazóis 2-piridil substituídos que são inibidores de transformação de crescimento fator-b(tgf-b)receptor tipo i (alk5) e/ou o receptor ativina tipo i (alk4), através de métodos de seu preparo e seu uso na medicina, especificamente no tratamento e prevenção de um estágio de doença rnediado por esses receptores.
BRPI0418765A 2004-04-21 2004-11-09 composto da fórmula (i) e composição farmacêutica BRPI0418765B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020040027591A KR100749566B1 (ko) 2004-04-21 2004-04-21 Ａｌｋ5 및/또는 ａｌｋ4 억제제로 유효한 2-피리딜이치환된 이미다졸 유도체
KR10-2004-0027591 2004-04-21
PCT/KR2004/002891 WO2005103028A1 (en) 2004-04-21 2004-11-09 2-pyridyl substituted imidazoles as alk5 and/or alk4 inhibitors

Publications (3)

Publication Number Publication Date
BRPI0418765A BRPI0418765A (pt) 2007-10-09
BRPI0418765B1 BRPI0418765B1 (pt) 2019-06-04
BRPI0418765B8 true BRPI0418765B8 (pt) 2021-05-25

Family

ID=35196912

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0418765A BRPI0418765B8 (pt) 2004-04-21 2004-11-09 composto da fórmula (i) e composição farmacêutica

Country Status (14)

Country Link
US (1) US7407958B2 (pt)
EP (1) EP1620426A1 (pt)
JP (1) JP4678540B2 (pt)
KR (1) KR100749566B1 (pt)
CN (1) CN1972921B (pt)
AU (1) AU2004318777B2 (pt)
BR (1) BRPI0418765B8 (pt)
CA (1) CA2564442C (pt)
IL (1) IL178757A (pt)
MX (1) MXPA06012096A (pt)
NO (1) NO20064771L (pt)
RU (1) RU2348626C2 (pt)
WO (1) WO2005103028A1 (pt)
ZA (1) ZA200609626B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8410146B2 (en) * 2004-04-21 2013-04-02 Sk Chemicals Co., Ltd. 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors
US8420685B2 (en) * 2004-04-21 2013-04-16 Sk Chemicals Co., Ltd. 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors
US20080319012A1 (en) * 2004-04-21 2008-12-25 In2Gen Co., Ltd. 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors
TR201901929T4 (tr) 2005-02-08 2019-03-21 Genzyme Corp TGFBeta'ya antikorlar.
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
WO2009115572A2 (en) * 2008-03-21 2009-09-24 Novartis Ag Novel heterocyclic compounds and uses therof
WO2009146301A1 (en) * 2008-05-27 2009-12-03 Yale University TARGETING TGF-β AS A THERAPY FOR ALZHEIMER'S DISEASE
US20100087486A1 (en) * 2008-05-30 2010-04-08 Hiroshi Nakamura Methods for using tgf-b receptor inhibitors or activin-like kinase (alk) 5 inhibitors a-83-01 and sb-431542 to treat eye disease and wound healing conditions
US8080568B1 (en) * 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
USRE47141E1 (en) 2010-06-29 2018-11-27 EWHA University—Industry Collaboration Foundation Methods of treating fibrosis, cancer and vascular injuries
US8513222B2 (en) 2010-06-29 2013-08-20 EWHA University—Industry Collaboration Foundation Methods of treating fibrosis, cancer and vascular injuries
WO2013078286A1 (en) 2011-11-22 2013-05-30 Cornell University Methods for stimulating hematopoietic recovery by inhibiting tgf beta signaling
RU2475243C1 (ru) * 2012-02-16 2013-02-20 Федеральное государственное бюджетное учреждение науки Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) Средство, обладающее антигипертензивной активностью
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
KR102434226B1 (ko) * 2016-06-30 2022-08-19 한미약품 주식회사 Alk5 억제제로서의 신규 피라졸 유도체 및 이의 용도
AU2017329090B9 (en) 2016-09-19 2019-09-05 Novartis Ag Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
CA3057969A1 (en) 2017-05-02 2018-11-08 Novartis Ag Combination therapy
CN110066277B (zh) * 2018-01-24 2021-07-23 上海璎黎药业有限公司 芳香杂环取代烯烃化合物、其制备方法、药物组合物和应用
EP3969449B1 (en) 2019-05-13 2025-02-12 Novartis AG New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
JP2023509760A (ja) 2020-01-08 2023-03-09 シンシス セラピューティクス，インコーポレイテッド Ａｌｋ５阻害剤複合体およびその使用
CN112266378B (zh) * 2020-11-09 2021-10-12 延边大学 含吲唑结构的咪唑类衍生物及其制备方法和应用
US12240830B2 (en) * 2021-08-13 2025-03-04 Bisichem Co., Ltd. Fused ring heteroaryl compounds and use thereof
CN115747214B (zh) * 2022-07-12 2025-11-18 安徽理工大学 Mlph基因在制备治疗尘肺病药物中的应用
CN121712526A (zh) 2023-06-13 2026-03-20 辛瑟斯治疗股份有限公司 抗cd5抗体及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656644A (en) * 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
DK0786455T3 (da) * 1994-09-26 2004-03-29 Shionogi & Co Imidazolderivater
US5965583A (en) * 1997-04-24 1999-10-12 Ortho-Mcneil Pharmaceutical, Inc. Substituted imidazoles useful in the treatment of inflammatory disease
DE60001229T2 (de) * 1999-04-09 2003-10-30 Smithkline Beecham Corp., Philadelphia Triarylimidazole
CO5271680A1 (es) * 2000-02-21 2003-04-30 Smithkline Beecham Corp Compuestos
GB0007405D0 (en) * 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
EP1391452A4 (en) 2001-05-25 2005-10-26 Mochida Pharm Co Ltd 4-HYDROXPIPERIDIN DERIVATIVE ANALGETIC EFFECT
JP2003040888A (ja) * 2001-07-30 2003-02-13 Sankyo Co Ltd イミダゾール誘導体
GB0218079D0 (en) * 2002-08-03 2002-09-11 Boatman Peter J A pipe and pipe assembly
MXPA05002981A (es) 2002-09-18 2005-06-22 Pfizer Prod Inc Nuevos compuestos de imidazol como inhibidores del factor de crecimiento transformante (tgf).
US7250434B2 (en) * 2003-12-22 2007-07-31 Janssen Pharmaceutica N.V. CCK-1 receptor modulators

Also Published As

Publication number Publication date
AU2004318777B2 (en) 2008-10-16
JP4678540B2 (ja) 2011-04-27
IL178757A (en) 2011-08-31
EP1620426A1 (en) 2006-02-01
KR20050102752A (ko) 2005-10-27
JP2007533734A (ja) 2007-11-22
RU2006140989A (ru) 2008-05-27
ZA200609626B (en) 2008-08-27
AU2004318777A1 (en) 2005-11-03
CA2564442C (en) 2011-06-14
RU2348626C2 (ru) 2009-03-10
MXPA06012096A (es) 2007-11-20
US7407958B2 (en) 2008-08-05
US20050261299A1 (en) 2005-11-24
BRPI0418765B1 (pt) 2019-06-04
BRPI0418765A (pt) 2007-10-09
CN1972921B (zh) 2012-01-04
CN1972921A (zh) 2007-05-30
IL178757A0 (en) 2007-02-11
WO2005103028A1 (en) 2005-11-03
NO20064771L (no) 2007-01-19
CA2564442A1 (en) 2005-11-03
KR100749566B1 (ko) 2007-08-16

Similar Documents

Publication Publication Date Title
BRPI0418765B8 (pt) composto da fórmula (i) e composição farmacêutica
CY1123625T1 (el) Συνθεσεις και μεθοδοι για θεραπεια διαταραχων χρησης αλκοολης, πονου και αλλων ασθενειων
NO20084374L (no) Imidazoltiazolforbindelser for behandling av sykdom
HN2009001145A (es) Compuestos y composiciones como inhibidores de proteina quinasa
BRPI0805826A2 (pt) compostos espiro-substituìdos como inibidores de angiogênese, método de produção de um composto, composição farmacêutica e métodos de tratamento
CO6620028A2 (es) Imidazoles 2-piridil sustituidos como inhibidores terapéuticos de alk5 y/o alk 4
EA201170590A1 (ru) Ингибиторы рецептора фактора роста фибробластов-3 (fgfr-3) и способы лечения
TW200714604A (en) Substituted heterocycles and the uses thereof
SV2009003290A (es) Compuestos y composiciones como inhibidores de cinasa de proteina
ECSP099634A (es) Derivados de piridazinona útiles como inhibidores de glucano sintasa
NO20093009L (no) Kondensert ring heterocykel kinase modulatorer
EA201100311A1 (ru) Амидные производные гетероарилов и их применение в качестве активаторов глюкокиназы
NO20092470L (no) Substituerte diazepanforbindelser som orexinreseptorantagonister
UA100227C2 (uk) Заміщені n-фенілметил-5-оксопролін-2-аміди як антагоністи p2x7-рецептора та їх застосування
MX2009004699A (es) Compuestos de piridinona.
MX2009009843A (es) Compuestos espiro sustituidos como inhibidores de la angiogenesis.
CR10309A (es) "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1"
NO20090608L (no) Tyrosinkinaseinhibitorer
EA201001371A1 (ru) Конденсированные пиримидиноновые соединения как модуляторы trpv3
NI201100166A (es) Derivados de benzofuranilo utilizados como inhibidores de glucoquinasa
UA107783C2 (en) Isoindoline compounds for use in treating cancer
NO20084396L (no) Kombinasjonsterapi
HN2010002733A (es) Compuestos y composiciones como inhibidores de cinasa
MY151191A (en) Novel antibodies
EA201170659A1 (ru) Антитела к рецептору ii tgf-вета

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2260 DE 29/04/2014.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: EWHA UNIVERSITY COLLABORATION FOUNDATION (KR) ; SK

B25A Requested transfer of rights approved

Owner name: EWHA UNIVERSITY COLLABORATION FOUNDATION (KR)

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/06/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/06/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/11/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2800 DE 03-09-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.